{"url_path":"/sec/pktx/8-k/2026-06-17/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Items.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1128189/0001079973-26-000855-index.html","accession_number":"0001079973-26-000855","cik":"0001128189","ticker":"PKTX","issuer_name":"ProtoKinetix, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1128189/0001079973-26-000855-index.html","primary_entity_key":"0001128189","primary_entity_name":"ProtoKinetix, Inc."},"word_count":342,"has_tables":true,"body_markdown":"**Item 8.01. Other Items.**\n\n** **\n\nOn February 11, 2026, the Company formed a wholly\nowned subsidiary, SightPath Biotech LLC, an Ohio limited liability company (“SightPath”) with the purpose of developing the\nCompany’s first-in-class novel synthetic glycopeptide molecule (PKX-001) for the treatment of dry-eye disease and other ocular diseases,\nas well as other business pursuits. The patents supporting the development of dry-eye treatment and other ophthalmic indications are still\nheld by the Company. Based on two independent studies, one performed in May 2021 by IQVIA, a leading company in health science analytics,\nand one performed in March 2025 by Benoit & Cote, a renowned leader in intellectual property, whose analysis supported IQVIA’s\nvaluation findings, the present value of the patents and associated work done to develop the dry-eye disease treatment and other ophthalmic\nindications is approximately $253 million. The valuation reflects the combination of novel IP, market size, development stage, competitive\ndifferentiation, and the scarcity premium for first-in-class ophthalmic assets.\n\n \n\nOn March 31, 2026, the Company filed a Form 12b-25\nNotification of Late Filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 10-K”).\nOn May 15, 2026, the Company filed a Form 12b-25 Notification of Late Filing of the Company’s Quarterly Report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “2026 Q1 10-Q”). The Company is working on filing the 2025 10-K and the 2026 Q1 10-Q.\n\n \n\nOn June 17, 2026, the Board approved the repricing\nof options for a total of 61,190,000 shares of common stock of the Company from a $0.028 exercise price per share to $0.01 per share and\nextended the expiration date of the options from December 6, 2028 to December 6, 2030.\n\n \n\nAlso on June 17, 2026, the Board approved the\nrepricing of warrants to exercise 6,000,000 shares of common stock of the Company issued to one of its advisors from a $0.028 exercise\nprice per share to $0.01 per share and extended the expiration date of the warrants from December 12, 2028 to December 12, 2030."}